MGI PHARMA is developing an extensive pipeline of novel therapeutic agents and supportive care products to treat patients. These product candidates are still in development, and as a result, their efficacy and safety has not been determined.

	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY REVIEW
Aloxi® Injection (post-op nausea and vomiting)
Aloxi® Oral Capsule (chemotherapy-induced nausea and vomiting)
Aquavan® Injection (sedation)
Saforis® (oral mucositis)
Dacogen® for Injection (Acute Myeloid Leukemia)
Dacogen® for Injection (Alternate dosing in myelodysplastic syndromes)
Amolimogene (cervical dysplasia)
ZYC300 (solid tumors)
GPI 21016 (chemo/radiation therapy sensitizer)
GCP II Inhibitors (chemo-induced neuropathy)